Monday, December 16, 2013

Indegene® and DrugLogic® to offer Full Lifecycle Drug Monitoring (FLDM) for insightful analysis of drug behavior, interactions, and safety

NEW YORKDec. 16, 2013 /PRNewswire-iReach/ -- Indegene ( and DrugLogic ( announced a joint offering for pharmaceutical companies and healthcare organizations that would combine the extensive medical expertise of Indegene with the sophisticated Big-Data analysis capabilities of DrugLogic's Qscan®. This knowledge and expertise-based offering combines sophisticated evidence-based statistical results, with experience-based physician monitoring, to help decipher a drug's clinical behavior and detect signals related to its safety and interactions with other factors.

full article

Media Contact:

Ann-Marie Craggan, Indegene Inc., +1 732.750.2901,

Steve Wordham, Druglogic, Inc, +1 800.393.1313